From Waste to Worth: Why Clinical Evidence is the Missing Link in Upcycled Nutraceuticals

“Tangible health claims beat fleeting emotions.”

Upcycling has emerged as one of the most compelling narratives in nutraceuticals, transforming agricultural byproducts, food waste, and fermentation side streams into valuable ingredients. But sustainability alone does not create lasting value. In this category, true differentiation comes from clinically proven health outcomes.

The Rise of Upcycled Nutrition

Companies are converting brewer’s spent grain, fruit pomace, and plant residues into proteins, fibers, and bioactives. Certification systems, such as those from the Upcycled Food Association, have strengthened the credibility of sustainability claims.

Yet consumers ultimately buy outcomes, not origin stories.

The Gap: Sustainability Without Efficacy

A protein must support muscle. A fiber must support gut health. Many upcycled ingredients rely on compositional or mechanistic data rather than human clinical outcomes. This limits differentiation, regulatory strength, and consumer trust.

A minority of upcycled nutraceutical ingredients, likely 20-30% based on industry observation, have at least one moderate-quality human clinical study. Most remain at the preclinical or mechanistic stages.

Today’s consumer expects sustainability, transparency, and proof. The most compelling narrative is: “This ingredient improves your health and does so sustainably.”

Additionally, regulators increasingly demand substantiated claims and therefore, clinically validated ingredients are better positioned for global acceptance and premium positioning.

Clinical Validation as a Value Multiplier

To unlock full value, ingredients must evolve into clinically validated solutions. This requires human trials, biomarker-driven endpoints, and clear health outcomes.

The strongest proof point comes from fermentation-derived ingredients. Fermentation is also a highly sustainable bioprocessing technology because it can utilize low-value agricultural byproducts, food-processing side streams, spent biomass, and other residual feedstocks as inputs. Through microbial conversion, these otherwise underutilized resources are transformed into high-value bioactive compounds such as postbiotics, beta-glucans, proteins, enzymes, and specialty metabolites. This makes fermentation a compelling example of how waste streams can be converted into clinically relevant nutraceutical ingredients.

EpiCor (from Cargill; originally developed by Embria Health Sciences) is a yeast fermentate postbiotic derived from Saccharomyces cerevisiae, supported by multiple human clinical studies in immune and gut health. Similarly, Wellmune (from Kerry Group) and BetaVia (from Kemin Industries) are beta-glucan ingredients derived from yeast or algae biomass with strong clinical evidence supporting immune health benefits.

These examples demonstrate that side-stream or biomass-derived inputs can successfully transition into premium, clinically validated nutraceutical ingredients.

Clinical validation for an upcycled ingredient remains essential even when the source material is already well studied. The biological activity of the original ingredient cannot automatically be assumed for its upcycled counterpart because processing may significantly alter the bioactive profile.

For example, barley is known for cholesterol reduction through beta-glucan, but brewer's spent grain may deliver different health benefits due to its altered composition, including higher protein and fibre content. Likewise, while carrots are traditionally associated with vision health through beta-carotene, carrot pomace ingredients such as BeniCaros (from NutriLeads) are positioned around immune-supporting polysaccharides.

Relying on borrowed science creates risks for both regulatory acceptance and market differentiation. Proprietary clinical validation is therefore essential to establish the true activity and value of upcycled ingredients.

Upcycled Waste Streams and Their Nutraceutical Potential

A wide range of agricultural and food-processing side streams are now being converted into nutraceutical ingredients:

• Brewer's spent grain containing proteins, fibres, arabinoxylans and gut-health ingredients (e.g., EverGrain)
• Fruit pomace containing polyphenols, antioxidants and functional fibres
• Carrot pomace containing immune-active polysaccharides (e.g., BeniCaros)
• Potato processing streams leading functional fibres (e.g., Solnul)
• Olive and wine production residues containing polyphenols and cardiometabolic bioactives (e.g., Hytolive, Vintera)
• Hemp processing streams containing dietary fibres and bioactive compounds (e.g., Brightseed)
• Fermentation biomass and yeast side streams containing postbiotics and beta-glucans (e.g., EpiCor, Wellmune, BetaVia)

Across the industry, the most common ingredient classes generated from upcycled streams include:

• Dietary fibres (~40-50%)
• Polyphenols and antioxidants (~20-30%)
• Proteins and peptides (~15-20%)
• Beta-glucans and postbiotics (~5-10%)
• Lipids and speciality bioactives (~5-10%)

Interestingly, the categories that currently possess the strongest clinical evidence, particularly beta-glucans, postbiotics and select fibres, also represent some of the most commercially successful examples of upcycled nutraceutical innovation.

Conclusion

“Waste to wealth” becomes meaningful only when supported by clinical proof. The future of upcycled nutraceuticals lies in combining sustainability with rigorous science, transforming not just waste streams, but human health.

For companies looking to commercialize upcycled ingredients, several strategic imperatives stand out:

• Invest early in clinical trials
• Focus on specific health outcomes
• Build scientific partnerships
• Integrate sustainability and efficacy into one compelling narrative

Clinical studies do not always need to be large, but they must be well-designed, carefully executed, and capable of withstanding regulatory scrutiny. Emerging approaches such as precision recruitment, biomarker-driven study designs, and adaptive trials can improve the return on investment from clinical research while reducing development risk.

Ultimately, sustainability may attract initial attention, but clinical evidence is what creates lasting commercial value. The next generation of successful upcycled nutraceuticals will be those that can demonstrate not only where they came from, but also what measurable health benefits they deliver.